Study on switching from combined therapy with fluticasone and salmeterol (Adair Discus) to that with fluticasone and formoterol (Flutiform) in elderly patients with asthma
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-UMIN000018449
- Lead Sponsor
- Teikyo University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
Those who meet any of the following criteria below at Visit 1 are ineligible: 1) Previous diseases/complications: - Those in whom respiratory tract infection or upper respiratory tract inflammation is seen. Those who the investigator judges are eligible are to be included even if any of the following complications is seen: infections other than respiratory tract infection, hyperthyroidism, hypertension, heart diseases, diabetes, and hypercalcemia. - Those who the investigator judges are ineligible due to serious heart/liver/kidney/lung/blood diseases or other serious complications - Those who have or have had malignant tumors in the past 5 years - Those who have antibiotic-resistant infections or deep mycosis - Those who had an aggravation of asthma requiring hospitalization, urgent treatment, or changes in drugs for long-term control within 4 weeks of enrollment 2) Medications/therapies - Those who developed moderate or worse adverse drug reactions requiring medications or other treatments when treated with ICS or/and LABA - Those who are taking SABA regularly or for preventive purposes, including those who are taking drugs for asthma attack improperly (using unapproved dosage/administration) 3) Others - Those who cannot properly use inhalants - Those who cannot properly undergo a respiratory function test - Those who the investigator or sub-investigator judges are ineligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method